See Selank/Semax blend dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
The Selank/Semax blend pairs two Russian-developed regulatory peptides — the tuftsin analog Selank and the ACTH 4-7 analog Semax — into a single co-administered preparation that researchers explore for combined anxiolytic and nootropic effects. This data captures the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting this blend.
The Selank/Semax blend is a co-formulated preparation of the two heptapeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences by the Ashmarin/Myasoedov-era research network — Selank (the tuftsin analog with a Pro-Gly-Pro stability tail) and Semax (the ACTH 4-7 fragment with the same Pro-Gly-Pro tail). The mechanistic rationale for combining the two molecules in a single preparation is straightforward overlap: Selank is positioned in the Russian clinical literature as a non-benzodiazepine anxiolytic with light cognitive effects, and Semax is positioned as a neuroprotective and cognitive-enhancing agent with a milder anxiolytic component.
The Selank/Semax Blend is a research-grade combination of two Russian heptapeptides — Selank (an anxiolytic tuftsin analog) and Semax (a nootropic ACTH(4-10) analog) — packaged in one vial and most often sourced for "calm-and-focused" cognitive research. It ships as a lyophilized powder you reconstitute with bacteriostatic water. See the standalone [Selank](/vendors/selank) and [Semax](/vendors/semax) entries for full pharmacology.
No pharmacology is unique to the blend; the proposed mechanism is the sum of the two parent peptides — Selank's GABA-A subunit-expression modulation and enkephalinase inhibition, plus Semax's BDNF/TrkB upregulation and dopaminergic-serotonergic modulation. No study has directly characterised pharmacokinetic or pharmacodynamic interactions between the two when co-administered.
No registered clinical trial has tested the blend specifically; all published Russian clinical evidence used the two molecules as separate products. Vendor packaging is a convenience and cost-saving format rather than a characterised combination product.
Selank/Semax Blend has a reported half-life of ~30 min (both components), and the dose intervals researchers model most often fall around twice daily (intranasal). Both peptides are very short-lived in plasma and act as pulses; neither accumulates between doses. Consistent timing matters more than total daily amount. Selank/Semax Blend is a blend of Selank and Semax, so a reconstitution figure for it covers the combined vial contents rather than any single component. It is catalogued under Memory Peptides on WPA.
263 Selank/Semax Blend reconstitution calculations have been logged by the WPA community. The most common dose entered is 500mcg (64 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (135 sessions). The most common dosing frequency is daily (7x/week) (29 logged protocols), followed by 5x/week (13).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.